Related Experiment Videos
Diclofenac does not modify morphine bioavailability in cancer patients
Franco De Conno1, Carla Ripamonti, Mauro Bianchi
1Pain Therapy and Palliative Care Division, National Cancer Institute, MilanItaly Department of Pharmacology, University of Milan, MilanItaly.
Pain
|March 1, 1992
Summary
Diclofenac does not alter morphine levels in cancer patients. This combination is safe for managing cancer pain, reducing risks of overdose and side effects from morphine.
Area of Science:
- Oncology
- Pharmacology
- Pain Management
Background:
- Cancer pain management often involves opioid analgesics like morphine.
- Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used for adjunctive pain relief.
- Potential drug interactions between opioids and NSAIDs require investigation.
Purpose of the Study:
- To investigate the pharmacokinetic interaction between morphine and diclofenac.
- To determine if diclofenac affects morphine bioavailability in cancer patients.
- To assess the safety of combining diclofenac with morphine for cancer pain.
Main Methods:
- Plasma concentrations of morphine were measured in 6 cancer patients.
- Measurements were taken before and during a 5-day administration of diclofenac.
- Pharmacokinetic analysis was performed to assess bioavailability.
Main Results:
- Diclofenac administration did not significantly alter morphine plasma concentrations.
- Morphine bioavailability remained unchanged in the presence of diclofenac.
- No evidence of increased morphine exposure or accumulation was observed.
Conclusions:
- Diclofenac can be safely co-administered with morphine in cancer patients.
- The combination does not increase the risk of morphine overdosage or adverse effects.
- This finding supports the use of diclofenac as an adjunct therapy for cancer pain.